{"success":true,"data":{"pressRelease":{"id":"162142","rtpr_id":"nGNXcdBKKD-20261006","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law ","author":"Globe Newswire","published_at":"2026-10-06T14:21:26.094Z","article_body":"LOS ANGELES, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=GKi-SJI9dU-qtEWixPTYaBnYp0PCWiepYj975dbWQMkAf0ZYpvp9q-9UJWjBVrUc9LjeqmCm0-mGxSJTPeX4Tuvg9oYpjDxqiKsTeKrXQD0X5iZSs2W1yH2tS-UmPmuo)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the\nCompany”) (NASDAQ: ARDX\n(https://www.globenewswire.com/Tracker?data=2z644uSYQbNno87Fy46MjOFicf0S6S85EQTekMtwapo9Cg3a8VncyZq4RpBqGT9PXNtNf0fboKVLdBTlOwbGcVmmndRxs1rmbXixg83SCuA=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of ARDX during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: January 13, 2025 to August 6, 2026\n\nDEADLINE: November 16, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=FYKPsbhe7fFmRHuv7oOJZKFIhbyhaBUyZLt1BF2cNz0C3VHsAYdhEgbXfHVuWKtfK8ZfaY2D7PePal5uKoykVqKC468Fz5JMeS13AYm4dpwhUlp_A8TYcGixOA_P61Q1).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Ardelyx faced reimbursement barriers\nimpacting patient access to XPHOZAH and IBSRELA. New-patient starts and\nprescription fulfillment were delayed by increasingly stringent prior\nauthorization and step-edit requirements. These challenges impacted the\nCompany’s commercial performance. Based on these facts, the Company’s\npublic statements were false and materially misleading throughout the class\nperiod. When the market learned the truth about Ardelyx, investors suffered\ndamages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=ZMZToF9w7K5IJIJvObARXVgKVyqHyk6hWVb_N0ykH2F_5YgpLftbFocNl_106vTX7jZkVCTR0j4ovaWiHV75ZZv6LWexS3mgiw5tb6ql4pRJtGc3VYbo7IHksi_rrfKS)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nSchall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXcdBKKD-20261006","title":"ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law ","author":"Globe Newswire","ticker":"ARDX","created":"2026-10-06T14:21:26.094Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=GKi-SJI9dU-qtEWixPTYaBnYp0PCWiepYj975dbWQMkAf0ZYpvp9q-9UJWjBVrUc9LjeqmCm0-mGxSJTPeX4Tuvg9oYpjDxqiKsTeKrXQD0X5iZSs2W1yH2tS-UmPmuo)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the\nCompany”) (NASDAQ: ARDX\n(https://www.globenewswire.com/Tracker?data=2z644uSYQbNno87Fy46MjOFicf0S6S85EQTekMtwapo9Cg3a8VncyZq4RpBqGT9PXNtNf0fboKVLdBTlOwbGcVmmndRxs1rmbXixg83SCuA=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of ARDX during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: January 13, 2025 to August 6, 2026\n\nDEADLINE: November 16, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=FYKPsbhe7fFmRHuv7oOJZKFIhbyhaBUyZLt1BF2cNz0C3VHsAYdhEgbXfHVuWKtfK8ZfaY2D7PePal5uKoykVqKC468Fz5JMeS13AYm4dpwhUlp_A8TYcGixOA_P61Q1).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Ardelyx faced reimbursement barriers\nimpacting patient access to XPHOZAH and IBSRELA. New-patient starts and\nprescription fulfillment were delayed by increasingly stringent prior\nauthorization and step-edit requirements. These challenges impacted the\nCompany’s commercial performance. Based on these facts, the Company’s\npublic statements were false and materially misleading throughout the class\nperiod. When the market learned the truth about Ardelyx, investors suffered\ndamages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=ZMZToF9w7K5IJIJvObARXVgKVyqHyk6hWVb_N0ykH2F_5YgpLftbFocNl_106vTX7jZkVCTR0j4ovaWiHV75ZZv6LWexS3mgiw5tb6ql4pRJtGc3VYbo7IHksi_rrfKS)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\nSchall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T14:21:26.144865349Z","server_sent_at_ms":1791296486144},"received_at":"2026-10-06T14:21:26.196Z","source_url":null},"analysis":{"id":"150635","press_release_id":"162142","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Active securities fraud class action against Ardelyx alleging misleading statements about XPHOZAH/IBSRELA reimbursement and patient-access issues"],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP issued a solicitation reminding ARDX investors of a pending securities fraud class action with a lead plaintiff deadline of November 16, 2026.\n\nThe complaint alleges Ardelyx made misleading statements regarding reimbursement barriers for XPHOZAH and IBSRELA, including prior-authorization and step-edit requirements that delayed new-patient starts and hurt commercial performance during the class period of January 13, 2025 to August 6, 2026.\n\nThis is law-firm marketing rather than a new issuer disclosure; the class has not yet been certified.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; only note the underlying reimbursement allegations if independently confirmed."},"keyFigures":{},"quotedText":"Ardelyx faced reimbursement barriers impacting patient access to XPHOZAH and IBSRELA.","namedEntities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"founding partner, Schall, Brown & Schwartz LLP"}],"products":["XPHOZAH","IBSRELA"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"target of securities class action"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Schall, Brown & Schwartz LLP seeking lead plaintiffs for an already-filed class action against Ardelyx. No new issuer disclosure, no certified class, and no settlement amount announced."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"substantiveAllegation":"drug reimbursement headwinds"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP issued a solicitation reminding ARDX investors of a pending securities fraud class action with a lead plaintiff deadline of November 16, 2026.\n\nThe complaint alleges Ardelyx made misleading statements regarding reimbursement barriers for XPHOZAH and IBSRELA, including prior-authorization and step-edit requirements that delayed new-patient starts and hurt commercial performance during the class period of January 13, 2025 to August 6, 2026.\n\nThis is law-firm marketing rather than a new issuer disclosure; the class has not yet been certified.","key_figures":{},"named_entities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Andrew Brown","role":"founding partner, Schall, Brown & Schwartz LLP"}],"products":["XPHOZAH","IBSRELA"],"companies":[{"name":"Ardelyx, Inc.","ticker":"ARDX","relationship":"target of securities class action"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T14:21:31.113Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"substantiveAllegation":"drug reimbursement headwinds"}},"durationMs":4903,"modelName":"glm-5.3-flashx"}}